177 related articles for article (PubMed ID: 24481627)
1. Serum levels of matrix metalloproteinase-9 predict lymph node metastasis in breast cancer patients.
Heo DS; Choi H; Yeom MY; Song BJ; Oh SJ
Oncol Rep; 2014 Apr; 31(4):1567-72. PubMed ID: 24481627
[TBL] [Abstract][Full Text] [Related]
2. Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer.
Daniele A; Zito AF; Giannelli G; Divella R; Asselti M; Mazzocca A; Paradiso A; Quaranta M
Anticancer Res; 2010 Sep; 30(9):3521-7. PubMed ID: 20944132
[TBL] [Abstract][Full Text] [Related]
3. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
Sliwowska I; Kopczyński Z
Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer.
Shah FD; Shukla SN; Shah PM; Shukla HK; Patel PS
Indian J Cancer; 2009; 46(3):194-202. PubMed ID: 19574670
[TBL] [Abstract][Full Text] [Related]
5. Elevated expression of both MDR1 and MMP-2 genes in metastasized lymph node of invasive ductal breast cancer.
Lu LS; Chen L; Ding WX; Li K; Wu JJ
Eur Rev Med Pharmacol Sci; 2012 Dec; 16(15):2037-43. PubMed ID: 23280016
[TBL] [Abstract][Full Text] [Related]
6. Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression.
Patel S; Sumitra G; Koner BC; Saxena A
Clin Biochem; 2011 Jul; 44(10-11):869-72. PubMed ID: 21565179
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast.
Sullu Y; Demirag GG; Yildirim A; Karagoz F; Kandemir B
Pathol Res Pract; 2011 Dec; 207(12):747-53. PubMed ID: 22030137
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer.
Przybylowska K; Kluczna A; Zadrozny M; Krawczyk T; Kulig A; Rykala J; Kolacinska A; Morawiec Z; Drzewoski J; Blasiak J
Breast Cancer Res Treat; 2006 Jan; 95(1):65-72. PubMed ID: 16267613
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
10. Prediction of metastatic breast cancer in non-sentinel lymph nodes based on metalloprotease-1 expression by the sentinel lymph node.
Eiró N; González LO; Atienza S; González-Quintana JM; Beridze N; Fernandez-Garcia B; Pérez-Fernández R; García-Caballero T; Schneider J; Vizoso FJ
Eur J Cancer; 2013 Mar; 49(5):1009-17. PubMed ID: 23063352
[TBL] [Abstract][Full Text] [Related]
11. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution.
Wu CY; Wu MS; Chiang EP; Chen YJ; Chen CJ; Chi NH; Shih YT; Chen GH; Lin JT
Clin Cancer Res; 2007 Apr; 13(7):2054-60. PubMed ID: 17404086
[TBL] [Abstract][Full Text] [Related]
12. Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma.
Patel BP; Shah PM; Rawal UM; Desai AA; Shah SV; Rawal RM; Patel PS
J Surg Oncol; 2005 May; 90(2):81-8. PubMed ID: 15844188
[TBL] [Abstract][Full Text] [Related]
13. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
14. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
[TBL] [Abstract][Full Text] [Related]
15. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer.
Tamura M; Oda M; Matsumoto I; Tsunezuka Y; Kawakami K; Ohta Y; Watanabe G
Ann Surg Oncol; 2004 Oct; 11(10):928-33. PubMed ID: 15383417
[TBL] [Abstract][Full Text] [Related]
16. Preoperative serum levels of matrix metalloproteinase-2 (MMP-2) and survival of breast cancer among Korean women.
Song N; Sung H; Choi JY; Han S; Jeon S; Song M; Lee Y; Park C; Park SK; Lee KM; Yoo KY; Noh DY; Ahn SH; Lee SA; Kang D
Cancer Epidemiol Biomarkers Prev; 2012 Aug; 21(8):1371-80. PubMed ID: 22634108
[TBL] [Abstract][Full Text] [Related]
17. Low serum level of pro-matrix metalloproteinase 2 correlates with aggressive behavior in breast carcinoma.
Kuvaja P; Talvensaari-Mattila A; Pääkkö P; Turpeenniemi-Hujanen T
Hum Pathol; 2006 Oct; 37(10):1316-23. PubMed ID: 16949931
[TBL] [Abstract][Full Text] [Related]
18. MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer.
Quaranta M; Daniele A; Coviello M; Venneri MT; Abbate I; Caringella ME; Di Tardo S; Divella R; Trerotoli P; Di Gennaro M; Schittulli F; Fransvea E; Giannelli G
Anticancer Res; 2007; 27(5B):3593-600. PubMed ID: 17972522
[TBL] [Abstract][Full Text] [Related]
19. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
20. The predictive value of serum soluble E-cadherin levels in breast cancer patients undergoing preoperative systemic chemotherapy.
Hofmann G; Balic M; Dandachi N; Resel M; Schippinger W; Regitnig P; Samonigg H; Bauernhofer T
Clin Biochem; 2013 Oct; 46(15):1585-9. PubMed ID: 23792261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]